NeuroMetrix, Inc. (Nasdaq: NURO) reported today that industry insiders
got their first look at Quell during day 1 of this year’s International
Consumer Electronics Show (CES).
Quell utilizes NeuroMetrix’s proprietary non-invasive neurostimulation
technology to provide relief from chronic pain, particularly nerve pain
such as due to diabetes and lower back problems.
Public University System (APUS) today announced that its
undergraduate programs have been named for the third consecutive year to
U.S. News & World Report’s annual
qualitative ranking of top online degree programs.
- Discuss interim results for Study 202 evaluating PEGPH20 with gemcitabine and ABRAXANE® in pancreatic cancer patients - - Review current clinical development plan to evaluate PEGPH20 in two Non-Small Cell Lung Cancer trials, in combination with chemotherapy and then with a PD-1 inhibitor -
- Provide 2015 financial guidance - SAN DIEGO , Jan.
SecurityNational Mortgage Company, a wholly owned subsidiary of Security
National Financial Corporation (NASDAQ: SNFCA), is pleased to announce
that it has completed all payment obligations under its settlement
agreement with Wells Fargo Bank, N.A. The original settlement agreement
was made on April 7, 2011 to resolve the claims and disputes between
Wells Fargo and SecurityNational Mortgage Company regarding certain
mortgage loans that Wells Fargo had purchased from SecurityNational
Binkow & Goldberg LLP announces that a class action lawsuit has
been filed in the United States District Court for the Northern District
of California on behalf of a class (the “Class”) comprising purchasers
of the securities of FireEye,
Inc. (“FireEye” or the “Company”) (NASDAQ:FEYE) between January 2,
2014 and November 4, 2014, inclusive (the “Class Period”). Investors who
have losses of $100,000 or more are encouraged to contact the firm for
Health Net of California, Inc., a subsidiary of Health
Net, Inc. , and John
Muir Health have formed an Accountable Care Organization (ACO)
serving Health Net members utilizing John Muir Health’s medical centers
and its physician network in Contra Costa, Solano and Alameda counties.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 33rd Annual J.P. Morgan Healthcare
Conference on Tuesday, January 13, 2015, at 11:30 a.m. Pacific Time in
Starbucks Coffee Company (NASDAQ:SBUX) today introduced a new core
espresso offering with the launch of the Flat White handcrafted espresso
beverage, available at participating Starbucks ® stores
in the US and Canada.
Gilead Sciences, Inc. (Nasdaq:GILD) and Phenex Pharmaceuticals AG, a
privately-held biotechnology company, today announced the signing of a
definitive agreement under which Gilead will acquire Phenex’s Farnesoid
X Receptor (FXR) program comprising small molecule FXR agonists for the
treatment of liver diseases including nonalcoholic steatohepatitis
(NASH). Under the terms of the agreement, Gilead will pay Phenex an
upfront payment plus additional payments based upon achievement of
certain development milestones that may potentially be worth up to $470
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, announced today that its
Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief
Financial and Operating Officer, Philip Serlin, will be presenting at
the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham
Union Square Hotel in San Francisco, CA.
Kentucky Board of Medical Imaging and Radiation Therapy (KBMIRT) has
released two new online services, offering both professionals and
citizens increased access to licensee information and a more convenient
license renewal process.
plc (NASDAQ: ALKS) today announced topline results from FORWARD-1,
one of a series of supportive clinical studies in the comprehensive
FORWARD phase 3 pivotal program for ALKS 5461, a once-daily, oral
investigational medicine with a novel mechanism of action for the
adjunctive treatment of major depressive disorder (MDD). The FORWARD-1
study was designed to evaluate the safety and tolerability of two
titration schedules of ALKS 5461.
VIRGINIA BEACH, VA --
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.